TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02092961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib 100mg twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fostamatinib
Description: Fostamatinib 100mg twice daily.
Study: NCT04763863

Intervention type: OTHER
Intervention: Body Assessment Tool
Description: Assessment tool to evaluate stoma to find proper ostomy products

Intervention type: OTHER
Intervention: Clinical usability evaluation of the Body Assessment Tool
Description: The stoma care nurses evaluated the clinical usability of the Body Assessment Tool, which included answering the following questions:~Does the tool offer value in clinical practice? Does it provide a good starting point when choosing ostomy product(s)? Does it help raise the quality of care? Participants provided their responses on a 6 point-scale (1-6), where 1 indicated the lowest satisfaction and 6 the greatest satisfaction with the tool.
Study: NCT02789098

Intervention type: OTHER
Group type: OTHER
Intervention: (15)-O water positron emission tomography and Biomarkers
Description: Coronary endothelial function is assessed using (15)-O water positron emission tomography and cold pressor test . The response to the test is defined by the percentage increase myocardial blood flow . Assessment of fibrosis, inflammation an endothelial function is performed using biomarkers.
Study: NCT02092961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab 40 mg by subcutaneous injection every 2 weeks for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Fostamatinib
Description: Placebo bid for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Fostamatinib
Description: Placebo bid for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Adalimumab
Description: Placebo injection once every two weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Adalimumab
Description: Placebo injection once every two weeks.
Study: NCT04551079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: TAK-994 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: TAK-994 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: TAK-994 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-994 placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-994 placebo-matching tablets.
Study: NCT01598649

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fabricated foods with lupin protein
Description: - Foods containing altogether 25 g lupin protein isolate (bread, roll, sausage, spread)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: - Placebo capsules containing mannitol (four capsules per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: - Placebo capsules containing mannitol (four capsules per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arginine
Description: - Capsules containing arginine (four capsules per day with a total daily dosage of 1,6 g)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fabricated foods with milk protein
Description: Foods containing altogether 25 g milk protein isolate (bread, roll, sausage, spread)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fabricated foods with milk protein
Description: Foods containing altogether 25 g milk protein isolate (bread, roll, sausage, spread)
Study: NCT03283865

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance for caudal block
Description: The attending anesthesiologist will perform or instruct the placement of a caudal block according to their standard of practice. At the time of administration of local anesthetic into the caudal space, the study collaborator (SC) will ultrasound the caudal space keeping the provider placing the block blinded to the imaging. The provider placing the block will inject 0.5mL of preservative free saline. The provider will then be asked to state if they are correctly in the caudal space or not. If the provider feels they are not in the caudal space, they will re-do the procedure. If the provider fails to identify incorrect location and this is noted by ultrasound, the SC will inform the provider to re-do the procedure
Study: NCT01264393

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shape Up Rhode Island + Online Resources
Description: Participants will receive Shape Up Rhode Island, which is a 12-week statewide physical activity and weight loss campaign in addition to online weight loss resources

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shape Up Rhode Island + Online Weight Loss Program
Description: Participants will receive Shape Up Rhode Island, a 12-week statewide physical activity and weight loss campaign in addition to an online weight loss program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shape Up Rhode Island + Online Weight Loss Program + Group sessions
Description: Participants will receive Shape Up Rhode Island, a 12-week statewide physical activity and weight loss campaign in addition to an online weight loss program and the option of attending group sessions
Study: NCT00177229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based treatment
Description: 20 weekly group contacts with individual coaching over first 6 months, brief monthly contacts over next 6 months, no contacts over last 6 months. Medical monitoring throughout study period.
Study: NCT03981458

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyalofemme
Description: Gel made with hyaluronic acid to be applied vaginally to treat atrophic vaginitis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ialuril
Description: Bladder instillation of hyaluronic acid to treat recurrent UTI.
Study: NCT01944046

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Double blind phase Placebo Nasal Spray
Description: This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except oxytocin will NOT be added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: double Blind Oxytocin Nasal Spray
Description: Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Open Label intranasal oxytocin
Description: All participants who completed the 24 week double blind phase were eligible to join a 24 week open label phase in which all participants received intranasal oxytocin
Study: NCT02264795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine 2% with epinephrine 5mcg/ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride Solution
Study: NCT01637753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine(BCNU)
Description: Carmustine Sustained Release Implant

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Surgery
Description: Routine tumor resection surgery
Study: NCT02494284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 6-month DAPT followed by clopidogrel monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin plus clopidogrel
Description: standard long-term dual antiplatelet strategies (24-month DAPT followed by aspirin monotherapy)
Study: NCT03631979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intestinal lavage with normal saline
Description: Specially trained pediatric surgeon will administer 10ml/kg pre-warmed (37oC) normal saline via a single-use rectal tube of size 6FR twice per day, aiming at a depth of maximum 10 cm/kg, starting after randomization and not later than 24 hours of age, and continued until full enteral nutrition of 170ml/kg/day is achieved or NEC diagnosis (Bell stage II or more) is established, which one comes first. However, the intervention will be applied at a maximum of 2 weeks from birth.
Study: NCT01015989

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CARE+ Kenya brief computer risk assessment session
Description: The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. We will repeat the session every 3 months up to 9 months total.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CARE+ Kenya computer counseling session
Description: The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. The computer will let patients look at short videos on various HIV medicine and HIV risk reduction topics and will then help patients create a health plan. Patients will get an anonymous print out at the end of the session and can choose to share with health care provider. There are questions about depression, suicide, or domestic violence. If a patient's answers indicate that they may be depressed, suicidal, or currently in an abusive relationship, we will refer them to a health worker at the clinic. We will repeat the session every 3 months up to 9 months total.
Study: NCT00093769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib + rituximab
Description: Arm I: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients also receive rituximab IV on days 1, 8, and 15 of course 1 only and on day 1 of course 2 only. Treatment with repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.~* Arm II: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15 and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 only. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients in either arm may crossover to the other arm if treatment is found to be ineffective.
Study: NCT00644722

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MacIntosh Green Lite (metal single use laryngoscope blades)
Description: metal single use laryngoscope blades

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MacIntosh Green Spec II (metal reusable laryngoscope blades)
Description: metal reusable laryngoscope blades
Study: NCT01761747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ponatinib
Study: NCT02937545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Therapy Management
Description: Community pharmacists will provide medication therapy management in combination with pharmacogenetic testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Description: Community pharmacist will provide pharmacogenetic testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Description: Community pharmacist will provide pharmacogenetic testing.
Study: NCT02883725

Intervention type: OTHER
Intervention: data collection
Study: NCT04360265

Intervention type: OTHER
Group type: OTHER
Intervention: No Investigational Product
Description: No investigational product will be administered in this follow-up trial.

Intervention type: OTHER
Group type: OTHER
Intervention: No Investigational Product
Description: No investigational product will be administered in this follow-up trial.

Intervention type: DRUG
Group type: OTHER
Intervention: Adjuvant Immunomodulatory (IM) Therapy
Description: The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive IM therapy.
Study: NCT02504294

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Epoetin Hospira Arm
Description: Epoetin Hospira Arm: Epoetin Hospira will be administered intravenously (IV) per the analogous version of the Fresenius Medical Care North America (FMCNA) cMAB 1 (inclusive of version 1.0, 1.1,...)erythropoietin stimulating agents (ESA) dosing algorithm for Epoetin Hospira for 24 weeks. Subjects will have Epoetin Hospira initiated using the same ESA dose level and frequency of administration for Epogen prior to randomization into the trial. Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care Arm
Description: Standard of care arm: No interventions will be performed in this arm for the clinical study; and subjects will receive ongoing standard of care, which includes Epogen administered IV per the FMCNA cMAB 5 (inclusive of versions 5.0, 5.1,....) ESA dosing algorithm and IV iron per the FMCNA protocol that is standard of care, at FMCNA clinics during the contemporaneous 24 week period.

Intervention type: DRUG
Group type: OTHER
Intervention: IV Iron
Description: Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.

Intervention type: DRUG
Group type: OTHER
Intervention: IV Iron
Description: Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.
Study: NCT04595708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: Calls were made by volunteers trained to engage with participants. Call structure was unscripted and call length was recommended to be between 5-10 min.
Study: NCT03437499

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sustained Inflation
Description: Application of positive pressure by face mask with T-piece resuscitator for a prolonged period of 15 seconds at a peak pressure of 25 cmH20 followed by PEEP set at 5 cmH2O

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positive Pressure Ventilation
Description: Application of positive pressure by face mask with T-piece resuscitator at a peak pressure of 25 cmH20, PEEP set at 5 cmH2, for 40 inflations/minute
Study: NCT01999504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAL-2
Description: meal
Study: NCT04867967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iyengar Yoga
Description: Classical Iyengar Yoga intervention, especially designed for headache patients. Note: First administered face-to-face, due to Covid-restrictions changed to online classes
Study: NCT01999504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TFH-1
Description: Meal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reference
Description: Meal
Study: NCT01412723

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate as dietary supplementation
Description: Ferrous sulfate as dietary supplementation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron amino acid chelated as dietary supplementation
Description: Iron amino acid chelated as dietary supplementation
Study: NCT03446443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Honghe Fujie lotion
Description: Before application，wash the vaginal area with water and dry it. Take10ml Hong He Fujie into dilution bottles，added to 100ml with warm boiled water, using diluted lotion for the rinse of vulva and vagina, twice daily for 7days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Suppositories
Description: Before bedtime，wash the vaginal area and put 0.5g Metronidazole Suppositories into posterior vaginal fornix，once daily for 7days.
Study: NCT03877718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1: CL-H1T
Description: One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 18.75 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 2: CL-H1T
Description: One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 37.5 mg)
Study: NCT04867967

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based stress reduction
Description: Standardazied Mindfulness-based stress reduction intervention Note: First administered face-to-face, due to Covid-restrictions changed to online classes
Study: NCT03877718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 3: Sumatriptan Succinate 100 mg capsule
Description: One capsule of sumatriptan succinate 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 4: Promethazine HCl 18.75 mg
Description: One capsule of promethazine HCl 18.75 mg
Study: NCT01442623

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Rehabilitation
Description: The patients in the Nintendo Wii Vestibular Rehabilitation group will undergo a standardised 6 week program of vestibular rehabilitation using the Nintendo Wii Fit Plus at home 5 times a week. They will perform a series of exercises and games on the Wii Fit Plus that are designed to challenge and retrain balance. They will be seen once a week by a physiotherapist for review and progression of exercises.~Patients in the Conventional Vestibular Rehabilitation group will undergo a standardised program of conventional vestibular rehabilitation using conventional balance exercises (Herdman 2007) 5 times a week. They will be seen once a week by a physiotherapist to progress exercises and will receive a standardised home exercise program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation
Description: The patients in the Nintendo Wii Vestibular Rehabilitation group will undergo a standardised 6 week program of vestibular rehabilitation using the Nintendo Wii Fit Plus at home 5 times a week. They will perform a series of exercises and games on the Wii Fit Plus that are designed to challenge and retrain balance. They will be seen once a week by a physiotherapist for review and progression of exercises.~Patients in the Conventional Vestibular Rehabilitation group will undergo a standardised program of conventional vestibular rehabilitation using conventional balance exercises (Herdman 2007) 5 times a week. They will be seen once a week by a physiotherapist to progress exercises and will receive a standardised home exercise program.
Study: NCT04477954

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen
Description: Hyperbaric oxygen therapy (HBOT): inhalation of pressurized oxygen through a hyperbaric chamber (Revitalair430)
Study: NCT01774929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTS-fentanyl
Description: TTS-fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
Study: NCT03735368

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine Injection
Description: Dexmedetomidine Injection 1 μg/kg then 0.5-1 μg/kg/h infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injection
Description: Dexmedetomidine Injection 1 μg/kg then 0.5-1 μg/kg/h infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: placebo oral capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin Oral Capsule
Description: 150 mg pregabalin Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: topical anesthesia
Description: topical anesthesia of the eye by Benoxinate Hydrochloride 0.4% Eye Drops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical anesthesia
Description: topical anesthesia of the eye by Benoxinate Hydrochloride 0.4% Eye Drops
Study: NCT03191526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-0761 0.3 mg/kg IV
Description: Intravenous injection every 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: Intravenous injection every 12 weeks.
Study: NCT01332318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP13512
Description: XP13512 once daily for 16 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP13512
Description: XP13512 once daily for 16 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: one 50 mg dose of diphenhydramine (DPH) on day 16

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: XP13512 placebo once daily for 16 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: XP13512 placebo once daily for 16 days
Study: NCT01721759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT01657552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Each tablet contains 100 mg of Eltrombopag (Dose 200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Each tablet contains 100 mg of Eltrombopag (Dose 200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Each tablet contains 100 mg of Eltrombopag (Dose 200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: Each capsule contains 200 mg of Boceprevir (Dose 800 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: Each capsule contains 200 mg of Boceprevir (Dose 800 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Each tablet contains 375 mg of Telaprevir (Dose 750 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Each tablet contains 375 mg of Telaprevir (Dose 750 mg)
Study: NCT02544633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD265
Description: MGCD265 is a small molecule multi-targeted receptor tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD265
Description: MGCD265 is a small molecule multi-targeted receptor tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD265
Description: MGCD265 is a small molecule multi-targeted receptor tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD265
Description: MGCD265 is a small molecule multi-targeted receptor tyrosine kinase inhibitor